Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer
Open Access
Abstract
The ETS family member ERG is a transcription factor with physiological roles during development and in the vascular and hematopoietic systems. ERG oncogenic activity characterizes several malignancies, including Ewing’s sarcoma, leukemia and prostate cancer (PCa). In PCa, ERG rearrangements with androgen-regulated genes—mostly TMPRSS2—characterize a large subset of patients across disease progression and result in androgen receptor (AR)-mediated overexpression of ERG in the prostate cells. Importantly, PCa cells overexpressing ERG are dependent on ERG activity for survival, further highlighting its therapeutic potential. Here, we review the current understanding of the role of ERG and its partners in PCa. We discuss the strategies developed in recent years to inhibit ERG activity, the current therapeutic utility of ERG fusion detection in PCa patients, and the possible future approaches to target ERG fusion-positive tumors.Keywords
Funding Information
- European Research Council (ERC) (648670)
- Prostate Cancer Foundation (19YOUN16)
This publication has 204 references indexed in Scilit:
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer CellsPLOS ONE, 2013
- Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene ExpressionCell, 2013
- A transcriptional repressor co‐regulatory network governing androgen response in prostate cancersThe EMBO Journal, 2012
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate CancerCancer Cell, 2011
- Genome‐wide analysis of ETS‐family DNA‐binding in vitro and in vivoThe EMBO Journal, 2010
- An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer ProgressionCancer Cell, 2010
- Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in CancerCell, 2009
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)Cancer, 2009
- Distinct genomic aberrations associated with ERG rearranged prostate cancerGenes, Chromosomes and Cancer, 2009
- The role of the ETS factor erg in zebrafish vasculogenesisMechanisms of Development, 2008